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Introduction
Systemic mastocytosis (SM) is a rare disease characterized
by proliferation of aberrant mast cells. Mast cells have an
important role in anaphylactic reactions. Anaphylaxis
against venom of the species Hymenoptera can be a life
threatening complication in SM. Unfortunately, it is
unpredictable which patients will respond with anaphy-
laxis after wasp stings.
Mast cells and basophils arise from myeloid cell lineage,
but out of different precursor cells. Despite this, these cells
are similar in appearance and function. Both cells are sti-
mulated to degranulate by direct triggering, crosslinking of
IgE on the cell surface or by the complement system.
Different from mast cells, basophils can easily be isolated
from peripheral blood. A Basophil Activation Test (BAT)
is used to detect and predict anaphylactic reactions against
Hymenoptera venom in vitro.
Aim
The aim of this study is to investigate whether a BAT
can be used to predict which SM patients will develop
anaphylactic reactions for wasps’ venom of the species
Hymenoptera.
Patients and methods
26 SM patients were studied of which 8 had a history of
anaphylactic reaction against wasp sting. A BAT was per-
formed with the use of wasp allergen of the species
Hymenoptera. The BAT was intended for in vitro deter-
mination of expression of CD63 surface marker (a
transmembrane protein that fuses with the cellular mem-
brane in degranulation) and CCR3 (a constitutively
expressed chemokine for basophil activation) on baso-
phils in EDTA conserved whole blood by flowcytometry
upon antigen stimulation in order to evaluate patients’
hypersensitivity for Hymenoptera venom.
Results
Among the 8 patients with a history of anaphylaxis, we
found only one positive BAT for allergen of the species
Hymenoptera. In 18 patients without a history of ana-
phylactic reactions, none had a positive BAT.
Conclusion
A BAT is not useful for predicting anaphylactic reac-
tions against Hymenoptera venom in patients suffering
from SM.
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